icon-arrow-top icon-arrow-right icon-arrow-bottom icon-arrow-left icon-close 404 icon-zoom icon-linkedin icon-dpt-clinical icon-dpt-finance icon-dpt-hr icon-dpt-it icon-dpt-legal icon-dpt-market icon-dpt-marketing icon-dpt-medical icon-dpt-pharmaceutical icon-dpt-regulatory icon-dpt-research icon-creativity icon-passion icon-respect icon-results icon-microscope icon-curious icon-honest icon-pioneering
  • en
  • Contact Us
MedDay Pharmaceuticals
  • About Us
    • Our story
    • Management team
    • Board of directors
    • Scientific advisory board
    • Find us
  • Research & Development
    • Discovery at MedDay
    • Pipeline
  • For Patients & Families
    • Clinical trials
    • What is metabolism?
    • Expanded Access Policy (US Only)
  • News & Events

Research & Development

  • Homepage
  • •
  • Research & Development

Discovery at MedDay

Our metabolomics platform, SPECMET, has the ability to identify specific metabolic signatures in major central nervous system disorders, providing numerous opportunities for further pipeline development. By focusing on compounds that already have known activity in neurometabolic pathways, we believe we can quickly demonstrate clinical proof of concept.

Read more

Pipeline

Our pipeline currently comprises one lead candidate, MD1003, which has been developed into and through clinical trials, including two phase III studies in Progressive Multiple Sclerosis.

Read more
©MedDay Pharmaceuticals 2014-2021, All rights reserved
  • Site map
  • Legal terms
  • Transparency
  • Find us
  • Report an adverse event / safety information
  • Medical information request
  • Request on quality product and services
Updated on June 2nd, 2020 - COM-257-003
Back to top